Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fausto Castagnetti

Showing results (1-10 of 158) with videos related to

Pageof 16
Sort By:
Blood|May 15, 2025
How I Evaluate and Treat Resistance and Relapse in CMLSimona Soverini, Fausto Castagnetti
Nature Reviews. Clinical Oncology|November 3, 2016
Tyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom?Gianantonio Rosti, Fausto Castagnetti, Gabriele Gugliotta, et al.
Annals of Hematology|March 28, 2015
A review of the European LeukemiaNet recommendations for the management of CMLMichele Baccarani, Fausto Castagnetti, Gabriele Gugliotta, et al.
Best Practice & Research. Clinical Haematology|December 5, 2009
Response definitions and European Leukemianet Management recommendationsMichele Baccarani, Fausto Castagnetti, Gabriele Gugliotta, et al.
Critical Reviews in Oncology/Hematology|May 14, 2011
Second-generation BCR-ABL inhibitors for frontline treatment of chronic myeloid leukemia in chronic phaseGianantonio Rosti, Fausto Castagnetti, Gabriele Gugliotta, et al.
Hemasphere|March 21, 2022
Current treatment approaches in CMLFausto Castagnetti, Gabriele Gugliotta, Simona Soverini, et al.
Frontiers in Oncology|April 2, 2021
Dosing Strategies for Improving the Risk-Benefit Profile of Ponatinib in Patients With Chronic Myeloid Leukemia in Chronic PhaseFausto Castagnetti, Fabrizio Pane, Gianantonio Rosti, et al.
Cancer Treatment Reviews|August 16, 2011
Physician's guide to the clinical management of adverse events on nilotinib therapy for the treatment of CMLGianantonio Rosti, Fausto Castagnetti, Gabriele Gugliotta, et al.
Aging|December 29, 2011
Imatinib in chronic myeloid leukemia elderly patientsGabriele Gugliotta, Fausto Castagnetti, Francesca Palandri, et al.
Expert Review of Hematology|March 27, 2014
Definition and treatment of resistance to tyrosine kinase inhibitors in chronic myeloid leukemiaMichele Baccarani, Fausto Castagnetti, Gabriele Gugliotta, et al.
Pageof 16

Showing results (1-10 of 158) with videos related to

Sort By:
Pageof 16
Blood|May 15, 2025
How I Evaluate and Treat Resistance and Relapse in CMLSimona Soverini, Fausto Castagnetti
Nature Reviews. Clinical Oncology|November 3, 2016
Tyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom?Gianantonio Rosti, Fausto Castagnetti, Gabriele Gugliotta, et al.
Annals of Hematology|March 28, 2015
A review of the European LeukemiaNet recommendations for the management of CMLMichele Baccarani, Fausto Castagnetti, Gabriele Gugliotta, et al.
Best Practice & Research. Clinical Haematology|December 5, 2009
Response definitions and European Leukemianet Management recommendationsMichele Baccarani, Fausto Castagnetti, Gabriele Gugliotta, et al.
Critical Reviews in Oncology/Hematology|May 14, 2011
Second-generation BCR-ABL inhibitors for frontline treatment of chronic myeloid leukemia in chronic phaseGianantonio Rosti, Fausto Castagnetti, Gabriele Gugliotta, et al.
Hemasphere|March 21, 2022
Current treatment approaches in CMLFausto Castagnetti, Gabriele Gugliotta, Simona Soverini, et al.
Frontiers in Oncology|April 2, 2021
Dosing Strategies for Improving the Risk-Benefit Profile of Ponatinib in Patients With Chronic Myeloid Leukemia in Chronic PhaseFausto Castagnetti, Fabrizio Pane, Gianantonio Rosti, et al.
Cancer Treatment Reviews|August 16, 2011
Physician's guide to the clinical management of adverse events on nilotinib therapy for the treatment of CMLGianantonio Rosti, Fausto Castagnetti, Gabriele Gugliotta, et al.
Aging|December 29, 2011
Imatinib in chronic myeloid leukemia elderly patientsGabriele Gugliotta, Fausto Castagnetti, Francesca Palandri, et al.
Expert Review of Hematology|March 27, 2014
Definition and treatment of resistance to tyrosine kinase inhibitors in chronic myeloid leukemiaMichele Baccarani, Fausto Castagnetti, Gabriele Gugliotta, et al.
Pageof 16